Abstract: The present invention relates to an injenane-type diterpene compound derived from Euphorbia kansui Liou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Abstract: The present invention relates to a diterpene compound derived from Aleurites fordii, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of Daphne genkwa, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.

Abstract: The present invention relates to an antiviral composition containing an Aleurites fordii or Daphne kiusiana extract or a fraction thereof as an active ingredient. In detail, extracts of Aleurites fordii or Daphne kiusiana or fractions thereof can induce the secretion of an immune-related cytokine, interferon-? (IFN-?) in natural killer (NK) cells, and thus exhibit potent antiviral activity and superior effects for viral diseases, and therefore can be effectively used in an antiviral composition.

Abstract: Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.

Abstract: The present invention relates to the elucidation of a gene that can act as a novel marker for liver cancer diagnosis and to diagnostic and prognostic measurements of liver cancer using the same. More specifically, it relates to a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU, MMP12, ESM-1, ABHD7, HCAPG, CXCL-3, Col5A2, MAGEA, GSN, CDC2, CST1, MELK, ATAD2, FAP and MSN and/or a method for diagnostic and prognostic measurement of liver cancer using the same. These have been discovered using normal liver tissues and liver cancer tissues collected from the same liver cancer patient of the present invention and represent the markers whose accuracy and reliability have been greatly improved as markers of liver cancer.

Abstract: The present invention relates to a composition for diagnosing colon cancer. The composition comprises at least one marker for measuring an mRNA or protein expression level of at least one gene specific for colon cancer. It can screen the genes which are overexpressed specifically only in colon cancer tissues or blood. The present invention can quantitatively analyze both the mRNA expression levels of the genes and the expression levels of the proteins encoded by the gene at the same time, thereby diagnosing colon caner of an early stage with a high level of reliability.

Abstract: The present invention relates to a method for detecting a colon cancer in a human, comprising the steps of: (a) providing a biological sample from the human; and (b) detecting the level of a ATAD2 nucleic acid or a ATAD2 protein in the biological sample, relative to the level of the ATAD2 nucleic acid or the ATAD2 protein in a control sample from a normal human, wherein an increased level of the ATAD2 nucleic acid or the ATAD2 protein in the biological sample compared to the control sample indicates that the human has the colon cancer. The biomarker of this invention was identified using normal colon tissue, colon cancer tissue and metastatic cancer tissue derived from a colon cancer patient. Therefore, the accuracy and reliability of the present biomarker for colon cancer and/or metastasis are much more significantly improved. In addition, the biomarker of this invention permits to identify and predict colon cancer or metastasis in an accurate manner.

Abstract: The present invention relates to a biomarker for gastric cancer, CST1 (cysteine proteinase inhibitor, type 2 family), DCC1 (Defective in sister chromatid cohesion homolog 1), IFITM1 (interferon induced transmembrane protein 1) or MELK (maternal embryonic leucine zipper kinase). More particularly, the present invention relates to a diagnostic composition for gastric cancer comprising an agent measuring the expression level of CST1, DCC1, IFITM1 or MELK, a kit comprising the composition, a method for detecting the marker, and a method for screening a therapeutic agent for gastric cancer using the marker.

Abstract: Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.

Abstract: Disclosed is a marker for diagnosis of liver cancer comprising polynucleotide useful for diagnosis of liver cancer. The marker for liver cancer diagnosis comprises at least one polynucleotide selected from a group consisting of the following polynucleotides (a) to (d):(a) polynucleotide having a base sequence defined by Seq. No. 1 or substantially similar sequence to Seq. No. 1; (b) polynucleotide encoding specific protein composed of an amino acid sequence defined by Seq. No. 2; (c) polynucleotide that comprises Seq. No. 2, in which at least one amino acid is substituted, deleted, inserted and/or added, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2; and (d) polynucleotide that is encoded by another polynucleotide hybridized with polynucleotide having Seq. No. 1 under stringent conditions, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2.

Abstract: The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, a cancer-related factor is specifically expressed in dendritic cells differentiated from a monocyte of human peripheral blood. Accordingly, the monoclonal antibody specific for the NDRG 2 protein, the protein chip comprising the same and the method for measuring a quantity and quality of the NDRG 2 protein by using the same can be applied to elucidate characteristics of the dendritic cell and perform a research on the NDRG 2. Therefore, the present invention may help clinically to investigate and treat intractable diseases and cancers using the dendritic cell.

Abstract: Disclosed is a diagnostic kit for gastric cancer. It comprises an agent capable of detecting and quantitatively assaying the gastric cancer marker Mac-2BP (Mac-2 binding protein). Also, a method for detecting the gastric cancer marker using the kit is disclosed.